Releases: vanallenlab/moalmanac-db
Releases · vanallenlab/moalmanac-db
2023 October 5 release
Added entries:
- (Preclinical) ATM copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) BAP1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) BARD1 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) CCNE1 copy number amplifications and sensitivity to dinaciclib in osteosarcoma.
- (Preclinical) CDK4 copy number amplifications and sensitivity to palbociclib in osteosarcoma.
- (Preclinical) CHEK2 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) FANCA copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) FGFR1 copy number amplifications and sensitivity to AZ4547 and PD173074 in osteosarcoma.
- (Preclinical) MYC copy number amplifications and sensitivity to AT7519 in osteosarcoma.
- (Preclinical) PTEN copy number deletions and sensitivity to MK-2206 and rapamycin in osteosarcoma.
- (Preclinical) RB1 somatic variants and sensitivity to olaparib and palbociclib in osteosarcoma.
- (Preclinical) TP53 copy number deletions and sensitivity to talazoparib in osteosarcoma.
- (Preclinical) TP53 somatic variants and sensitivity to NSC59984 in osteosarcoma.
Revised entries:
- (FDA) ERBB2 amplifications in metastatic breast cancer were revised to list invasive breast carcinoma as the cancer type.
- (FDA) TSC1 and TSC2 somatic variants and sensitivity to everolimus in subependymal giant cell astrocytoma were revised to include Oncotree terms and codes.
- (Preclinical) AKT1 somatic variants and p.E17K and sensitivity to MK-2206 were revised to include breast cancer as the Oncotree terms and code. The description was also updated for both cataloged relationships.
- (Preclinical) ATM p.A1127D, c.2251-10T>G, and shRNA knockdown and sensitivity to olaparib was revised to update the doi of the underlying journal article and properly list the Oncotree code.
- (Preclinical) CDKN2A copy number deletions and sensitivity to EPZ015666 was adjusted to inferential evidence because the underlying relationship is for MTAP deletions, which are commonly co-deleted with CDKN2A.
- (Preclinical) PTEN copy number deletions and somatic frameshift, nonsense, and splice site variants and sensitivity to AZD8186 were edited to add prostate cancer as the tumor type and the description was revised.
- (Preclinical) RB1 shRNA knockdowns and resistance to palbociclib in prostate cancer was revised to properly list the Oncotree code and term.
- (Inferential) COSMIC mutational signature 10 and sensitivity to pembrolizumab and durvalumab was revised to list any solid tumor as the cancer type.
publication_date was also added for all revised entries.
Removed entries:
- (Preclinical) PIK3CB and sensitivity to AZD8186.
2023 September 7 release
Added entries:
- (FDA) BRCA1 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA2 somatic and germline variants and sensitivity to abiraterone acetate in combination with niraparib for patients with metastatic castration-resistant prostate cancer.
- (FDA) MSI-H and sensitivity to dostarlimab-gxly in combination with carboplatin and paclitaxel, followed by single agent dostarlimab-gxly, in endometrial cancer.
Revised entries:
- (FDA) EGFR p.T790M and sensitivity to osimertinib, resolved typo in description.
- (FDA) RET fusions and sensitivity to pralsetinib, received regular approval from FDA after being previously granted accelerated approval.
- All prior entries have been revised to have
last_updateddate be in ISO 8601 date standard ofYYYY-MM-DD
Removed entries:
- (FDA) RET somatic variants and sensitivity to pralsetinib in medullary thyroid cancer was withdrawn voluntarily by Genentech.
The field publication_date has been added to entries added or modified in this release. Our team will populate this field for prior records over future releases.
2023 July 6 release
Added entries:
- (FDA) BRCA1 and BRCA2 somatic and germline variants and sensitivity to olaparib in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for patients with metastatic pancreatic adenocarcinoma.
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib for the treatment of adult patients with HER2-negative high risk early breast cancer.
- (FDA) ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C somatic variants and sensitivity to talazoparib in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer.
Revised entries:
- (FDA) BRCA1 and BRCA2 germline variants and sensitivity to olaparib in breast cancer. Revised description to add additional approval details from FDA drug label.
2023 April 6 release
Added entries:
- (FDA) BRAF p.V600E and sensitivity to dabrafenib in combination with trametinib for pediatric patients with low-grade glioma.
2023 February 2 release
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
Added entries:
- (FDA) ERBB2 copy number amplifications and sensitivity to trastuzumab in combination with tucatinib in colorectal cancer.
- (FDA) ESR1 somatic variants and sensitivity to elacestrant in breast cancer.
2023 January 5 release
In this release, we add two recent precision oncology approvals from the FDA.
Added entries:
- (FDA) IDH1 p.R132C, p.R132G, p.R132H, p.R132L, and p.R132S and sensitivity to olutasidenib in acute myeloid leukemia.
- (FDA) KRAS p.G12C and sensitivity to adagrasib in non-small cell lung cancer.
2022 December 1 release
In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.
Added entries:
- (FDA) RET fusions and sensitivity to selpercatinib in any solid tumor.
Revised entries:
- (Preclinical) PPARGC1A knockdown with CRSPR-Cas9 and not favorable prognosis in melanoma was changed from the feature type Silencing to Knockdown.
- (Preclinical) USP11 knockdown with siRNA and sensitivity to olaparib in osteosarcoma was changed from the feature type Silencing to Knockdown.
Removed entries:
- (Clinical evidence) High Neoantigen Burden and sensitivity to pembrolizumab in non-small cell lung cancer.
2022 October 6 release
Added entries:
- (FDA) FGFR2 rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.
Revised entries:
- (Clinical evidence) SPOP variants and favorable prognosis in prostate adenocarcinoma was changed to sensitivity to abiraterone. Additionally, the doi url was revised to correctly point to the citation.
2022 September 8 release
Added entries:
- (FDA) FGFR1 rearrangements and sensitivity to pemigatinib in myeloid/lymphoid neoplasms.
2022 August 4 release
Added entries:
- (FDA) ALK-EML4 and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
- (Clinical trial) BRCA1 and BRCA2 germline variants and sensitivity to olaparib.
- (Clinical evidence) BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
- (Clinical evidence) CDKN2A deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
- (Clinical evidence) MYOCD amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
- (Preclinical) RB1 copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
- (Preclinical) RB1 knockout and resistance to palbociclib in prostate cancer.
- (Preclinical) USP11 silencing and sensitivity to olaparib in osteosarcoma.
- (Inferential) ATRX copy number deletions and poor prognosis in leiomyosarcoma.
- (Inferential) BRCA1 and BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
- (Inferential) CDKN2C deletion may confer sensitivity to CDK4/6 inhibitors.
- (Inferential) MAP2K4 and MAPK7 copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.
- (Inferential) PDGFRA copy number amplification and poor prognosis in breast cancer.
- (Inferential) PTEN copy number deletion and poor prognosis in uterine leiomyosarcoma.
- (Inferential) PTEN copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma.